Survey on National List of Essential Medicine of Bangladesh

Section B: Background Information

Q7. What is your primary area of expertise?

Q8. What is your primary work setting?

Section C: Medicines to be Dropped

Instruction:

The draft revised EML is listed below by generic name and presented alphabetically. If you think a medicine should not remain in the EML:

Select option: No.
Choose the reason(s) for dropping it.
If possible, share a reference document (guideline or any scientific article or weblink) to support your reason.

You may suggest removing more than one medicine.

S/N	Name of the Medicine (to be selected from the drop-down menu)	Q9. Should this medicine remain in the EML?	Q10. If No, why? (select all that apply)
1	Abacavir (ABC)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
2	Abacavir + Lamivudine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
3	Abacavir, Dolutegravir,Lamivudine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
4	ACD Blood Pack/Double Bag/Triple Bag	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
5	Acetazolamide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
6	Acetylsalicylic acid (Aspirin)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
7	Actinomycin D/Dactinomycin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
8	Acyclovir	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
9	Adrenaline (Epinephrine)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
10	Albendazole	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
11	Albumin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
12	Alcohol based hand rub	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
13	Allopurinol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
14	Amikacin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
15	Amiodarone	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
16	Amitriptyline	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
17	Amlodipine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
18	Amoxicillin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
19	Amoxicillin + Clavulanic acid	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
20	Amphotericin B	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
21	Anastrozole	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
22	Anti-D immunoglobulin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
23	Anti-rabies immunoglobulin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
24	Anti-tetanus immunoglobulin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
25	Antivenom immunoglobulin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
26	Artemether + Lumefantrine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
27	Artesunate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
28	Ascorbic Acid (Vitamin C)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
29	Atomoxetine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
30	Atorvastatin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
31	Atracurium	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
32	Atropine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
33	Azathioprine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
34	Azithromycin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
35	Barium Sulphate (X-Ray Grade)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
36	BCG Vaccine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
37	Bedaquiline	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
38	Benzathine benzylpenicillin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
39	Benzyl Benzoate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
40	Betamethasone	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
41	Bicalutamide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
42	Bisacodyl	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
43	Bisoprolol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
44	Bleomycin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
45	Budesonide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
46	Budesonide+formoterol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
47	Bupivacaine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
48	Bupropion	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
49	Calamine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
50	Calcium folinate (leucovorin calcium)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
51	Calcium Gluconate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
52	Capecitabine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
53	Carbamazepine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
54	Carbimazole	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
55	Carboplatin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
56	Cefalexin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
57	Cefixime	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
58	Ceftazidime	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
59	Ceftriaxone	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
60	Cefuroxime	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
61	Chlorhexidine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
62	Chloroquine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
63	Chloroxylenol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
64	Cholera Fluid (Ringers lactate )	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
65	Cholera Vaccine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
66	Ciprofloxacin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
67	Cisplatin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
68	Clarithromycin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
69	Clindamycin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
70	Clofazimine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
71	Clomifene	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
72	Clonazepam	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
73	Clopidogrel	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
74	Clotrimazol ear drops	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
75	Clotrimazole	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
76	Cloxacillin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
77	Coagulation Factor IX, plasma-derived	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
78	Coagulation Factor VIII, plasma-derived	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
79	Colecalciferol (Vitamin D)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
80	Copper-containing device	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
81	Crisantaspase/ L-asparaginase / Asparaginase	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
82	Cyclophosphamide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
83	Cycloserine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
84	Dapsone	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
85	Deferoxamine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
86	Delamanid	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
87	Dexamethasone	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
88	Dextrose in Water	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
89	Diazepam	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
90	Digoxin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
91	Diphtheria Antitoxin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
92	Docetaxel	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
93	Dolutegravir	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
94	Dolutegravir + Lamivudine + Tenofovir	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
95	Domperidone	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
96	Doxorubicin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
97	Doxycycline	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
98	Efavirenz	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
99	Efavirenz + Lamivudine + Renofovir	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
100	Empagliflozin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
101	Enalapril	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
102	Enoxaprin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
103	Ephedrine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
104	Ergometrine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
105	Ethambutol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
106	Ethinylestradiol + Levonorgestrel	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
107	Ethionamide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
108	Etoposide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
109	Famotidine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
110	Fentanyl	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
111	Ferrous salt	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
112	Ferrous salt with Folic Acid	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
113	Fexofenadine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
114	Filgrastim	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
115	Fluconazole	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
116	Fluorescein	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
117	Fluorouracil	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
118	Fluoxetine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
119	Fluphenazine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
120	Folic Acid	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
121	Furosemide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
122	Gadoterate Meglumine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
123	Gemcitabine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
124	Gentamicin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
125	Gliclazide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
126	Glucose	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
127	Glucose with Sodium Chloride	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
128	Glycerin/Glycerol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
129	Glyceryl Trinitrate (Nitroglycerin)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
130	Haloperidol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
131	Heparin sodium	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
132	Hepatitis - B Vaccine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
133	Human Papilloma Virus (HPV) Vaccine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
134	Hydrochlorothiazide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
135	Hydrocortisone	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
136	Hydroxocobalamin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
137	hydroxychloroquine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
138	Hyoscine Butylbromide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
139	Ibuprofen	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
140	Imatinib	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
141	influenza vaccine (seasonal)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
142	Insulin injection (soluble)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
143	Intermediate-acting insulin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
144	Intraperitoneal dialysis solution (of appropriate composition)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
145	Iohexol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
146	Ipratropium bromide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
147	Isoflurane	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
148	Isoniazide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
149	Itraconazole	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
150	Ivermectin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
151	Ketamine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
152	Labetalol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
153	Lactulose	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
154	Lamivudine (3TC)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
155	Lamotrigine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
156	Letrozole	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
157	Levodopa + Carbidopa	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
158	Levofloxacin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
159	Levonorgestrel	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
160	Levonorgestrel IUD (LNG-IUS)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
161	Levonorgestrel-releasing implant	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
162	Levothyroxine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
163	Lidocaine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
164	Lidocaine + Epinephrine (adrenaline)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
165	Linezolid	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
166	Lithium Carbonate/Citrate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
167	Lopinavir + Ritonavir	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
168	Losartan	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
169	Magnesium Sulphate 50%	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
170	Mebendazole	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
171	Medroxyprogesterone Acetate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
172	Melphalan	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
173	Mercaptopurine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
174	Meropenem	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
175	Metformin Hydrochloride	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
176	Methotrexate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
177	Methyl Phenidate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
178	Methyldopa	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
179	Methyl-Prednisolone	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
180	Metoprolol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
181	Metronidazole	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
182	Miconazole	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
183	Mifepristone – Misoprostol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
184	Misoprostol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
185	Montelukast	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
186	Morphine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
187	Moxifloxacin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
188	MR Vaccine (Measles & Rubella)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
189	Multiple Micronutrient (Supplement)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
190	Naloxone	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
191	Natamycin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
192	Neostigmine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
193	Nevirapine (NVP)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
194	Nifedipine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
195	Nitrofurantoin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
196	Nitrous Oxide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
197	Noradrenaline	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
198	Nortriptyline	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
199	Nystatin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
200	Olanzapine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
201	Omeprazole	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
202	Ondansetron	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
203	Etonogestrel (One Rod Implant)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
204	Oral Rehydration Salts (ORS)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
205	Oxaliplatin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
206	Oxygen	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
207	Oxytocin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
208	Paclitaxel	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
209	Paracetamol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
210	Pentavalent Vaccine (DPT, HepatitisB , Hib)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
211	Permethrin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
212	Pethidine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
213	Phenobarbital	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
214	Phenoxymethylpenicillin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
215	Phenytoin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
216	Phytomenadione (Vitamin K)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
217	Pilocarpine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
218	Piperacillin + Tazobactam	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
219	Pneumococcal Vaccine(PCV)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
220	Poliomyelitis Vaccine(OPV & IPV))	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
221	Potassium Chloride	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
222	Potassium Permanganate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
223	Povidone-Iodine 10%	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
224	Pralidoxime Mesylate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
225	Prednisolone	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
226	Premixed Insulin (30/70)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
227	Pretomanid	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
228	Primaquine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
229	Procyclidine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
230	Progesterone Only Pill	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
231	Propranolol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
232	Protionamide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
233	Pyrazinamide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
234	Pyridoxine (Vitamin B6)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
235	Retinol (Vitamin A)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
236	Rifampicin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
237	Rifampicin + Isoniazid (2FDC)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
238	Rifampicin + Isoniazid + Ethambutol (3FDC)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
239	Rifampicin + Isoniazid + Pyrazinamide + Ethambutol (4FDC)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
240	Rifapentin + Isoniazd (3HP)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
241	Rifapentine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
242	Risperidone	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
243	Ritonavir	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
244	Rituximab -including quality-assured biosimilars	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
245	Rivaroxaban	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
246	Salbutamol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
247	Salicylic Acid	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
248	Sertraline	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
249	Silver Sulfadiazine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
250	Sodium Chloride	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
251	Sodium Valproate (Valproic acid)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
252	Sofosbuvir + Velpatasvir	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
253	Spironolactone	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
254	Streptokinase	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
255	Streptomycin Sulphate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
256	Sulfamethoxazole + Trimethoprim	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
257	Sulfasalazine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
258	Suxamethonium	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
259	Tamoxifen	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
260	TD Vaccine (Tetanus and Diphtheria)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
261	Telmisartan + Amlodipine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
262	Telmisartan + Hydrochlorothiazide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
263	Tenofovir Disoproxil Fumarate (TDF)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
264	Tetanus Toxoid Inj Vaccine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
265	Tetracaine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
266	Thiopental	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
267	Timolol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
268	Tiotropium	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
269	Tramadol	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
270	Tranexamic acid	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
271	Trastuzumab -including quality-assured biosimilars	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
272	Tropicamide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
273	Tuberculin, purified protein derivative (PPD)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
274	Typhoid Conjugated Vaccine	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
275	Vancomycin	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
276	Vecuronium Bromide	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
277	Verapamil	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
278	Vinblastine Sulphate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
279	Vincristine Sulphate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
280	Water for Injection (sterile/pyrogen free)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
281	Water Purification Chlorine Tablet	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
282	Xylometazoline	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
283	Zidovudine (ZDV or AZT)	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason
284	Zinc Sulfate	Yes No No Comments	Not addressing a major disease burden in Bangladesh
			Not recommended as first-line (or appropriate-line) therapy in national or international standard treatment guidelines
			An alternative medicine has more therapeutic benefits or is more cost-effective
			Other reason

Section D: Medicines to be Added – WHO Model List

Instruction: You may propose adding medicines from the WHO Model List of Essential Medicines that are not currently in the draft list.

Q12. Do you recommend adding any medicines from the WHO Model List?

Yes

Section E: Medicines to be Added – Not in WHO Model List

Instruction: You may also propose adding medicines not included in the WHO Model List, provided you can justify their importance for Bangladesh.

Q16. Do you recommend adding any medicines not in the WHO Model List?

Yes

Section F: Final Comments

Q22. Do you have any additional comments on the draft EML or this survey?